Subacute liver failure secondary to amyloid light-chain amyloidosis

Gastroenterology and Hepatology

Volumn 8, Issue 3, 2012, Pages 205-208

  Hydes, Theresa J ^a   Aspinall, Richard J ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; IODINE 123; PROTEIN;

ABDOMINAL DISCOMFORT; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSISTED VENTILATION; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DYSPNEA; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOFILTRATION; HEPATOMEGALY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; JAUNDICE; MALE; MYELOMA; NOSE FEEDING; PERIPHERAL EDEMA; PROTEIN BLOOD LEVEL; PROTEINURIA; SCINTIGRAPHY; URINALYSIS; WEIGHT REDUCTION;

EID: 84859570856     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909. (Pubitemid 27408573)
2. Varela M, De Las Heras D, Miquel R. Hepatic failure due to primary AL amyloidosis. J Hepatol. 2003;39:290. (Pubitemid 36920569)
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596. (Pubitemid 36951371)
4. Gillmore JD, Lovat LB, Hawkins PN. Amyloidosis and the liver. J Hepatol. 1999;30(suppl 1):17-33. (Pubitemid 29172498)
5. Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med. 1988;85:73-80.
6. Peters RA, Koukoulis G, Gimson A, Portmann B, Westaby D, Williams R. Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut. 1994;35:1322-1325. (Pubitemid 24277354)
7. Gregg JA, Herskovic T, Bartholomew LG. Ascites in systemic amyloidosis. Arch Intern Med. 1965;116:605-610.
8. Levy M, Polliack A, Lender M, Eliakim M. The liver in amyloidosis. Digestion. 1974;10:40-51.
9. Liu CJ, Chien RN, Huang SF, Chiang JM. Severe intrahepatic cholestasis in an elderly patient with primary amyloidosis and colon adenocarcinoma. Chang Gung Med J. 2004;27:74-79.
10. Rockey DC. Striking cholestatic liver disease: a distinct manifestation of advanced primary amyloidosis. South Med J. 1999;92:236-241. (Pubitemid 29093759)
11. Terada T, Hirata K, Hisada Y, Hoshii Y, Nakanuma Y. Obstructive jaundice caused by the deposition of amyloid-like substances in the extrahepatic and large intrahepatic bile ducts in a patient with multiple myeloma. Histopathology. 1994;24:485-487. (Pubitemid 24192321)
12. Couture P, LeBlanc F, Gagnon P, Gagnon O, Gagne C. Hyperlipidemia as the first biochemical manifestation of primary hepatic amyloidosis. Am J Gastroenterol. 1997;92:1046-1047. (Pubitemid 27237605)
13. Sandberg-Gertzen H, Ericzon BG, Blomberg B. Primary amyloidosis with spontaneous splenic rupture, cholestasis, and liver failure treated with emergency liver transplantation. Am J Gastroenterol. 1998;93:2254-2256. (Pubitemid 29076887)
14. Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998;42:727-734. (Pubitemid 28261065)
15. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82:291-298. (Pubitemid 37229464)
16. Hawkins PN, Aprile C, Capri G, et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med. 1998;25:701-708. (Pubitemid 28377032)
17. Lovat LB. Amyloidosis. In: Bircher J, Benhamou J, McIntyre N, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. 2nd ed. New York, NY: Oxford University Press; 1999.
18. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983;58:665-683. (Pubitemid 13019381)
19. Girnius S, Seldin DC, Skinner M, et al. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009;94:1029-1032.
20. Kumar KS, Lefkowitch J, Russo MW, et al. Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology. 2002;122:2026-2031. (Pubitemid 34651444)
21. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2011;90:201-206.
22. Velcade [package insert]. Cambridge, Mass: Millenium Pharmaceuticals; 2010.
23. San Miguel J, Bladé J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11:51-61.
24. Gertz MA, Kyle RA. Primary systemic amyloidosis-a diagnostic primer. Mayo Clin Proc. 1989;64:1505-1519. (Pubitemid 20032796)